Emylcamate

Emylcamate

Clinical data
ATC code	N05BC03 (WHO)
Identifiers
IUPAC name 3-methyl-3-pentanol carbamate
CAS Number	78-28-4 Y
PubChem CID	6526
ChemSpider	6278 Y
UNII	KCJ747D3R4
KEGG	D07317 Y
ChEMBL	ChEMBL2104208 N
CompTox Dashboard (EPA)	DTXSID40228645
ECHA InfoCard	100.001.002
Chemical and physical data
Formula	C7H15NO2
Molar mass	145.202 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OC(C)(CC)CC)N
InChI InChI=1S/C7H15NO2/c1-4-7(3,5-2)10-6(8)9/h4-5H2,1-3H3,(H2,8,9) Y Key:SLWGJZPKHAXZQL-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Emylcamate (marketed as Striatran by Merck) is an anxiolytic and muscle relaxant. It was patented in the US in 1961 (US Patent 2,972,564) and advertised for the treatment of anxiety and tension. It was claimed to be superior to meprobamate, which was the market leader at the time. It is no longer prescribed.

A study of the drug's effects in mice was done in 1959. It concluded that at 50 mg/kg emylcamate gave a 63% decrease in motor activity compared with meprobamate's 32% decrease, a doubling in effective potency. The therapeutic index in mice was also established:

Meprobamate	Emylcamate	Effect
175	123	ED50 (mg/kg)
600	550	LD50 (mg/kg)
3.4	4.4	Therapeutic index

Emylcamate also has a faster intra-parenteral onset than meprobamate, 3 minutes compared with 35.

Further reading

• Shorter E (August 2004). "Olhando para trás: um novo caminho possível para a descoberta de drogas em psicofarmacologia" [Looking back: a new possible path for drug discovery in psychopharmacology.] (PDF). Revista de Psiquiatria do Rio Grande do Sul (in Portuguese). 26 (2): 196–203. doi:10.1590/S0101-81082004000200009. Archived from the original (PDF) on 2006-07-21.

External links

• "Emylcamate". The Comparative Toxicogenomics Database.
• "Emylcamate". BIAM (in French).